Advertisement

IL-25: Regulator of Type 2 Inflammation in Allergic Nasal Mucosa

  • Shumin Liao
  • Kai Sen Tan
  • Mingmin Bi
  • Wei Liao
  • Yuan Chen
  • Haiyu HongEmail author
Allergy Prevention (DY Wang, Section Editor)
  • 1 Downloads
Part of the following topical collections:
  1. Topical Collection on Allergy Prevention

Abstract

Purpose of review

Allergic nasal mucosal inflammation generally refers to the development of allergic rhinitis characterized by IgE-mediated mast cell responses, eosinophil infiltration, and augmented Th2 cytokines/chemokine production in the nasal mucosa. However, due to the complexity of the disease, its detailed mechanism has yet to be fully elucidated. Hence, in this review, we aim to collate the studies of IL-25 pertaining to its role in allergic mucosal inflammation to help drive future research of IL-25 in utilizing it as a potential target in the management of allergic sinonasal diseases.

Recent findings

At the turn of the century, interleukin (IL)-25 was discovered as a novel member of the IL-17 cytokine family found to be derived mainly from nasal/airway epithelial cells, Th2 cells, and activated eosinophils. It is found to play a pivotal role in nasal allergic mucosal inflammation as a master regulator of promoting type 2 responses mediated by both Th2 cells and ILC2s, augmenting allergic inflammation. IL-25 is highly bioactive by mainly reacting through IL-25R/IL-17RB which activates a myriad of transcriptional factors including p38 MAPK, NF-κB, STAT 5, and Act1 which contributes to its role in allergic mucosal inflammation.

Summary

This review collated results that showed that IL-25 serves as a bridge between the epithelial cells and inflammatory cells in the sinonasal mucosa in promoting type 2 allergic inflammation, as well as between the innate immunity and acquired immunity via the feedback between ILC2s and Th2 cells to amplify and perpetuate allergic inflammation, which indicates IL-25 as a promising target for future biologics development.

Keywords

IL-25 IL-25R IL-17RB Th2 cells ILC2s Allergic inflammation 

Notes

Funding

This study was supported by the Science and Technology Planning Project of Guangdong Province (No. 2016A020215030 and 2017A020215180), and Natural Science Foundation of Guangdong Province (No. 2018A030313399).

Compliance with Ethics Guidelines

Conflict of Interest

Shumin Liao, Kai Sen Tan, Mingmin, Wei Liao, Yuan Chen, and Haiyu Hong declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Yao X, et al. Interleukin (IL)-25: Pleiotropic roles in asthma. Respirology. 2016;21(4):638–47.  https://doi.org/10.1111/resp.12707 This paper reviews the discovery, cellular origins and targets of IL-25 and summarizes both animal and humane studies on the role of IL-25 in asthma.CrossRefGoogle Scholar
  2. 2.
    Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pacific Allergy. 2011;1(3):157–67.  https://doi.org/10.5415/apallergy.2011.1.3.157.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    • Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255–81.  https://doi.org/10.1146/annurev.immunol.17.1.255 This review elucidates the characteristics of the pathogenesis in different stages of airway allergic responses.CrossRefGoogle Scholar
  4. 4.
    Broide DH, M.B.C.B. Allergic rhinitis: Pathophysiology. ALLERGY AND ASTHMA PROCEEDINGS. 2010.  https://doi.org/10.2500/aap.2010.31.3388.CrossRefGoogle Scholar
  5. 5.
    •• Fort MM, et al. IL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In Vivo. Immunity. 2001;15(6):985–95.  https://doi.org/10.1016/S1074-7613(01)00243-6 In this paper, IL-25 is first described as a Th2-derived cytokine using an IL-4/anti-IL-12 monoclonal antibody polarized murine model.CrossRefGoogle Scholar
  6. 6.
    Xiu Juan Yao XFLX. Potential Role of Interleukin - 25/Interleukin - 33/Thymic Stromal Lymphopoietin - Fibrocyte Axis in the Pathogenesis of Allergic Airway Diseases. Chinese Medical Journal. 2018;131(16).  https://doi.org/10.4103/0366.
  7. 7.
    Dong C. Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev. 2008;226(1):80–6.  https://doi.org/10.1111/j.1600-065X.2008.00709.x.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wang Y, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. The Journal of experimental medicine. 2007;204(8):1837–47.  https://doi.org/10.1084/jem.20070406.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tamachi T, et al. Interleukin 25 in Allergic Airway Inflammation. International Archives of Allergy and Immunology. 2006;140(1):59–62.  https://doi.org/10.1159/000092713.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Angkasekwinai P, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med. 2007;204(7):1509–17.  https://doi.org/10.1084/jem.20061675 This experimental article verifies that the IL-25 expressed by lung epithelial cells promotes the initiation of allergic type 2 responses on murine model.CrossRefGoogle Scholar
  11. 11.
    Kohanski MA, et al. Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2018;142(2):460-469.e7.  https://doi.org/10.1016/j.jaci.2018.03.019.CrossRefPubMedGoogle Scholar
  12. 12.
    Ikeda K, Nakajima H, Suzuki K, Kagami S, Hirose K, Suto A, et al. Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation. Blood. 2003;101(9):3594–6.  https://doi.org/10.1182/blood-2002.CrossRefPubMedGoogle Scholar
  13. 13.
    Kang C, Jang AS, Ahn MH, Shin JA, Kim JH, Choi YS, et al. Interleukin-25 and Interleukin-13 Production by Alveolar Macrophages in Response to Particles. American Journal of Respiratory Cell and Molecular Biology. 2005;33(3):290–6.  https://doi.org/10.1165/rcmb.2005-0003OC.CrossRefPubMedGoogle Scholar
  14. 14.
    Kouzaki H, Tojima I, Kita H, Shimizu T. Transcription of Interleukin-25 and Extracellular Release of the Protein Is Regulated by Allergen Proteases in Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology. 2013;49(5):741–50.  https://doi.org/10.1165/rcmb.2012-0304OC.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kouzaki H, Matsumoto K, Kikuoka H, Kato T, Tojima I, Shimizu S, et al. Endogenous Protease Inhibitors in Airway Epithelial Cells Contribute to Eosinophilic Chronic Rhinosinusitis. American Journal of Respiratory and Critical Care Medicine. 2017;195(6):737–47.  https://doi.org/10.1164/rccm.201603-0529OC.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kim DW, Kim DK, Eun KM, Bae JS, Chung YJ, Xu J, et al. IL-25 Could Be Involved in the Development of Allergic Rhinitis Sensitized to House Dust Mite. Mediators Inflamm. 2017;2017:3908049.  https://doi.org/10.1155/2017/3908049.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Petersen BC, A.L.B.A. IL-25 induces type 2 cytokine production in a novel, steroidresistant IL-17RB+ myeloid population that exacerbatesasthmatic pathology; 2015.  https://doi.org/10.1038/nm.2735.CrossRefGoogle Scholar
  18. 18.
    Angkasekwinai P, Park H, Wang YH, Wang YH, Chang SH, Corry DB, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. The Journal of Experimental Medicine. 2007;204(7):1509–17.  https://doi.org/10.1084/jem.20061675.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C. Regulation of IL-9 expression by IL-25 signaling. Nature Immunology. 2010;11(3):250–6.  https://doi.org/10.1038/ni.1846.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wang H, Mobini R, Fang Y, Barrenäs F, Zhang H, Xiang Z, et al. Allergen challenge of peripheral blood mononuclear cells from patients with seasonal allergic rhinitis increases IL-17RB, which regulates basophil apoptosis and degranulation. Clinical & Experimental Allergy. 2010;40(8):1194–202.  https://doi.org/10.1111/j.1365-2222.2010.03542.x.CrossRefGoogle Scholar
  21. 21.
    Matsumoto Y, Noguchi E, Imoto Y, Nanatsue K, Takeshita K, Shibasaki M, et al. Upregulation of IL17RB during natural allergen exposure in patients with seasonal allergic rhinitis. Allergol Int. 2011;60(1):87–92.  https://doi.org/10.2332/allergolint.10-OA-0230.CrossRefPubMedGoogle Scholar
  22. 22.
    Corrigan CJ, Wang W, Meng Q, Fang C, Eid G, Caballero MR, et al. Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. Journal of Allergy and Clinical Immunology. 2011;128(1):116–24.  https://doi.org/10.1016/j.jaci.2011.03.043.CrossRefPubMedGoogle Scholar
  23. 23.
    •• Licona-Limón P, et al. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14(6):536–42.  https://doi.org/10.1038/ni.2617 This is a good review on the new subset of type 2 innate lymphoid cells functioning to orchestrate the type 2 responses evoked by the epithelial cell-derived cytokines IL-25, IL-33 and TSLP.CrossRefGoogle Scholar
  24. 24.
    Hurst SD, et al. New IL-17 Family Members Promote Th1 or Th2 Responses in the Lung: In Vivo Function of the Novel Cytokine IL-25. The Journal of Immunology. 2002;169(1):443–53.  https://doi.org/10.4049/jimmunol.169.1.443.CrossRefPubMedGoogle Scholar
  25. 25.
    • Kim MR. Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood. 2002;100(7):2330–40.  https://doi.org/10.1182/blood-2002-01-0012 This paper is among the leads that succeed in identifying and cloning human IL-17E (IL-25) in mice to displace eosinophilia and increasing type 2 cytokine secretion.CrossRefGoogle Scholar
  26. 26.
    Yao XJ, Huang KW, Li Y, Zhang Q, Wang JJ, Wang W, et al. Direct comparison of the dynamics of IL-25- and ‘allergen’-induced airways inflammation, remodelling and hypersensitivity in a murine asthma model. Clinical & Experimental Allergy. 2014;44(5):765–77.  https://doi.org/10.1111/cea.12298.CrossRefGoogle Scholar
  27. 27.
    Yao X, Wang W, Li Y, Huang P, Zhang Q, Wang J, et al. IL-25 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma model. Respiratory Res. 2015;16:16(1)–1.  https://doi.org/10.1186/s12931-015-0197-3.CrossRefGoogle Scholar
  28. 28.
    Yao X, Wang W, Li Y, Lv Z, Guo R, Corrigan CJ, et al. Characteristics of IL-25 and allergen-induced airway fibrosis in a murine model of asthma. Respirology. 2015;20(5):730–8.  https://doi.org/10.1111/resp.12546.CrossRefPubMedGoogle Scholar
  29. 29.
    • Fallon PG, et al. Identification of an interleukin (IL)-25–dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. The Journal of Experimental Medicine. 2006;203(4):1105–16.  https://doi.org/10.1084/jem.20051615 This paper identifies a novel IL-4-, IL-5-, IL-13-producing non-B/ non-T(NBNT) population which leads to rapid helminth expulsion regulated by IL-25.CrossRefGoogle Scholar
  30. 30.
    Sharkhuu T, et al. Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity. Clin Exp Allergy. 2006;36(12):1575–83.  https://doi.org/10.1111/j.1365-2222.2006.02595.x.CrossRefPubMedGoogle Scholar
  31. 31.
    Wong CK, et al. Interleukin-25–Induced Chemokines and Interleukin-6 Release from Eosinophils Is Mediated by p38 Mitogen-Activated Protein Kinase, c-Jun N-Terminal Kinase, and Nuclear Factor-κB. Am J Respiratory Cell Mol Biol. 2005;33(2):186–94.  https://doi.org/10.1165/rcmb.2005-0034OC.CrossRefGoogle Scholar
  32. 32.
    Xu G, Zhang L, Wang DY, Xu R, Liu Z, Han DM, et al. Opposing roles of IL-17A and IL-25 in the regulation of TSLP production in human nasal epithelial cells. Allergy. 2010;65(5):581–9.  https://doi.org/10.1111/j.1398-9995.2009.02252.x.CrossRefPubMedGoogle Scholar
  33. 33.
    Su J, et al. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease. Inflammatory Bowel Dis. 2013;19(4):720–8.  https://doi.org/10.1097/MIB.0b013e3182802a76.CrossRefGoogle Scholar
  34. 34.
    •• Shin H, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2015;135(6):1476-1485.e7.  https://doi.org/10.1016/j.jaci.2015.01.003 This paper puts forward a nice idea that IL-25 may serve as a novel therapeutic target in patients with CRSwNP.CrossRefGoogle Scholar
  35. 35.
    Miljkovic D, Bassiouni A, Cooksley C, Ou J, Hauben E, Wormald PJ, et al. Association between Group 2 Innate Lymphoid Cells enrichment, nasal polyps and allergy in Chronic Rhinosinusitis. Allergy. 2014;69(9):1154–61.  https://doi.org/10.1111/all.12440.CrossRefPubMedGoogle Scholar
  36. 36.
    Matsushita K, Kato Y, Akasaki S, Yoshimoto T. Proallergic cytokines and group 2 innate lymphoid cells in allergic nasal diseases. Allergology International. 2015;64(3):235–40.  https://doi.org/10.1016/j.alit.2014.12.008.CrossRefPubMedGoogle Scholar
  37. 37.
    Wong CK, Li PW, Lam CWK. Intracellular JNK, p38 MAPK and NF-κB regulate IL-25 induced release of cytokines and chemokines from costimulated T helper lymphocytes. Immunol Lett. 2007;112(2):82–91.  https://doi.org/10.1016/j.imlet.2007.07.002.CrossRefPubMedGoogle Scholar
  38. 38.
    Li Z, Wang H, Liu L. Interleukin-25 Enhances Allergic Inflammation through p38MAPK and NF-κB Pathways in Mouse Models of Allergic Rhinitis. Iran J Allergy Asthma Immunol. 2014;13(6):412.PubMedGoogle Scholar
  39. 39.
    Liu J, Liu L, Cui Y, Zhang J, Jiang H. p38 MAPK regulates Th2 cytokines release in PBMCs in allergic rhinitis rats. J Huazhong Univ Sci Technolog Med Sci. 2010;30(2):222–5.  https://doi.org/10.1007/s11596-010-0218-x.CrossRefPubMedGoogle Scholar
  40. 40.
    Liu C, et al. A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation. Sci Signal. 2011;4(197):72.  https://doi.org/10.1126/scisignal.2001843.CrossRefGoogle Scholar
  41. 41.
    Claudio E, et al. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J Immunol. 2009;182(3):1617–30.  https://doi.org/10.4049/jimmunol.182.3.1617.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Swaidani S, et al. The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J Immunol. 2009;182(3):1631–40.  https://doi.org/10.4049/jimmunol.182.3.1631.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    London NJ, Tharakan A, Ramanathan MJ. The Role of Innate Immunity and Aeroallergens in Chronic Rhinosinusitis. Adv Otorhinolaryngol. 2016;79:69–77.  https://doi.org/10.1159/000445132.CrossRefPubMedGoogle Scholar
  44. 44.
    Mjosberg JM, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011;12(11):1055–62.  https://doi.org/10.1038/ni.2104.CrossRefPubMedGoogle Scholar
  45. 45.
    Lam M, Hull L, McLachlan R, Snidvongs K, Chin D, Pratt E, et al. Clinical severity and epithelial endotypes in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3(2):121–8.  https://doi.org/10.1002/alr.21082.CrossRefPubMedGoogle Scholar
  46. 46.
    Iinuma T, et al. Interleukin-25 and mucosal T cells in noneosinophilic and eosinophilic chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2015;114(4):289–98.  https://doi.org/10.1016/j.anai.2015.01.013.CrossRefPubMedGoogle Scholar
  47. 47.
    Lam M, Hull L, Imrie A, Snidvongs K, Chin D, Pratt E, et al. Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis. Am J Rhinol Allergy. 2015;29(3):175–81.  https://doi.org/10.2500/ajra.2015.29.4176.CrossRefPubMedGoogle Scholar
  48. 48.
    Lam EP, et al. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol. 2016;137(5):1514–24.  https://doi.org/10.1016/j.jaci.2015.10.019.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    • Chen F, et al. Nasal interleukin 25 as a novel biomarker for patients with chronic rhinosinusitis with nasal polyps and airway hypersensitiveness. Ann Allergy Asthma Immunol. 2017;119(4):310-316.e2.  https://doi.org/10.1016/j.anai.2017.07.012 This paper gives idea of considering IL-25 as a molecular indicator for AHR in patients with CRSwNP.CrossRefGoogle Scholar
  50. 50.
    •• Hong H, et al. Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2018;141(5):1890–2.  https://doi.org/10.1016/j.jaci.2017.10.050 Very good paper on the clinical application of IL-25 as an indicator to predict the prognosis of oral corticosteroid treated patients with CRSwNP.CrossRefGoogle Scholar
  51. 51.
    Ozturan A, Eyigor H, Eyigor M, Osma U, Yilmaz MD, Selcuk OT, et al. The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps. Eur Arch Otorhinolaryngol. 2017;274(1):283–8.  https://doi.org/10.1007/s00405-016-4260-6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Shumin Liao
    • 1
    • 2
  • Kai Sen Tan
    • 3
  • Mingmin Bi
    • 2
  • Wei Liao
    • 1
  • Yuan Chen
    • 1
  • Haiyu Hong
    • 1
    Email author
  1. 1.Department of OtolaryngologyThe Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhaiChina
  2. 2.Department of OtolaryngologyThe Seventh Affiliated Hospital of Sun Yat-sen UniversityShenzhenChina
  3. 3.Department of Otolaryngology, National University of SingaporeNational University Health SystemSingaporeSingapore

Personalised recommendations